M&A Deal Summary

Covidien Acquires ev3

On June 1, 2010, Covidien acquired healthcare services company ev3 for 2.6B USD

Acquisition Highlights
  • This is Covidien’s 2nd transaction in the Healthcare Services sector.
  • This is Covidien’s largest (disclosed) transaction.
  • This is Covidien’s 6th transaction in the United States.
  • This is Covidien’s 1st transaction in Minnesota.

M&A Deal Summary
Date 2010-06-01
Target ev3
Sector Healthcare Services
Buyer(s) Covidien
Deal Type Add-on Acquisition
Deal Value 2.6B USD

Target

ev3

Plymouth, Minnesota, United States
website
ev3 is the endovascular technology company that brings together the right people, technology, and resources to successfully identify and provide meaningful clinical solutions to underserved markets in the endovascular field. ev3 has been dedicated to developing breakthrough and clinically proven technologies for the endovascular treatment of peripheral vascular and neurovascular diseases.

Search 192,723 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Covidien

Dublin, Ireland

website

Category Company
Sector Medical Products
Employees38,500
Revenue 10.2B USD (2013)
DESCRIPTION
Covidien office in Plymouth, Minnesota.
Covidien office in Plymouth, Minnesota.

Covidien plc is a global healthcare technology and medical supplies provider. Covidien was formed as a spin-off from Tyco in 2007 and is based in Dublin, Ireland.

DEAL STATS #
Overall 7 of 21
Sector (Healthcare Services) 2 of 5
Type (Add-on Acquisition) 5 of 17
State (Minnesota) 1 of 1
Country (United States) 6 of 16
Year (2010) 1 of 1
Size (of disclosed) 1 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-11-06 Aspect Medical Systems

Norwood, Massachusetts, United States

Aspect Medical Systems, Inc. a market leader in brain monitoring technology. Aspect's Bispectral Index technology directly measures the effects of anesthetics and sedatives on the brain and has been used to assess more than 7.5 million patients.

Buy $210M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2012-01-05 BÂRRX Medical

Sunnyvale, California, United States

BARRX Medical, Inc. is a developer of endoscopic treatment solutions for Barrett's esophagus and other gastroenterological diseases such as esophageal squamous cell neoplasia, bleeding associated with radiation proctopathy, and bleeding associated with gastric antral vascular ectasia.

Buy $325M
Mergr

Product

Company

Legal